China Resources Sanjiu Medical & Pharmaceutical Co Ltd

The company maintains a conservative capital structure, with a debt-to-equity ratio of 0.3, indicating limited leverage. Free cash flow of 2.996 billion CNY supports operational flexibility, though net cash is negative after subtracting total debt, signaling potential liquidity constraints. A current ratio of 1.83 suggests adequate short-term liquidity to cover obligations.

Profitability metrics show a return on equity of 15.43% and a return on assets of 5.82%, both above the typical thresholds for the pharmaceutical industry, indicating strong capital efficiency and earnings generation. Gross profit of 17.055 billion CNY and operating income of 4.852 billion CNY reflect a healthy margin structure, though net income of 3.421 billion CNY is lower, suggesting operational or tax pressures.

Geographic and segment exposure is not explicitly detailed in the available data, but the company operates primarily in China, with a focus on domestic pharmaceutical markets. Revenue concentration in a single region may expose the company to regulatory and macroeconomic risks.

Outlook data is not provided in the input, but historical revenue of 31.603 billion CNY indicates a large base. Analysts have assigned a mean price target of 37.27 CNY, with a median of 36.00 CNY, and a mean recommendation of 2.09 (leaning toward buy).

Risk factors include medium liquidity risk due to negative net cash after debt and a low dilution risk, with no near-term pressure from share issuance. The company has not disclosed significant dilution sources in recent filings.

Recent events include analyst price targets and recommendations, with 10 buy ratings and 2 strong-buy ratings, but no hold or sell ratings. No major regulatory or operational events are disclosed in the input data.

China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals. This structural clarification establishes the company’s operational baseline within the broader market taxonomy, providing a clearer framework for sector-specific analysis. Alongside these classification updates, the company’s risk profile has been initialized with specific assessments. Dilution risk is currently rated as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment suggests that existing shareholders face limited pressure from equity dilution in the near term. Conversely, liquidity risk has been assessed at a medium level. This rating highlights potential considerations regarding the company’s ability to meet short-term obligations or the ease of trading its shares without significant price impact. Investors should monitor this metric as it balances against the low dilution risk to form a complete picture of financial stability. The company is currently tracked with two officers and no analyst coverage or index memberships recorded in the available data. With no top holders identified, the ownership structure remains opaque in this snapshot. These foundational metrics, combined with the new sector and risk classifications, provide the essential context for evaluating China Resources Sanjiu Med’s position in the healthcare market.